Vancomycin toxicity. What is the evidence for dose dependency?

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Adverse Drug Reactions and Toxicological Reviews

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7918897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How vancomycin is used in Australasia--a survey.

  1993cited by this paper
• The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.

  1993cited by this paper
• Stevens-Johnson-Type Reaction with Vancomycin Treatment

  1992cited by this paper
• Vancomycin-induced cytopenias.

  1992cited by this paper
• Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin

  1992cited by this paper
• Chrononephrotoxicity in rat of a vancomycin and gentamicin combination.

  1992cited by this paper
• Exchange transfusion and multidose activated charcoal following vancomycin overdose.

  1992cited by this paper
• Hearing thresholds in CAPD patients.

  1992cited by this paper
• Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles.

  1991cited by this paper
• Ototoxicity of vancomycin: an experimental study in guinea pigs.

  1991cited by this paper
• Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs.

  1990cited by this paper
• Nephrotoxicity of vancomycin, alone and with an aminoglycoside.

  1990cited by this paper
• Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin.

  1990cited by this paper
• Risk of Nephrotoxicity with Combination Vancomycin‐Aminoglycoside Antibiotic Therapy

  1990cited by this paper
• Vancomycin- and erythromycin-induced hearing loss in humans

  1989cited by this paper
• Mild nephrotoxicity associated with vancomycin use.

  1989cited by this paper
• Aminoglycoside-induced hearing loss in humans

  1989cited by this paper
• Vancomycin and nephrotoxicity.

  1989cited by this paper
• Effect of intravenous vancomycin on renal function.

  1989cited by this paper
• Audiologic Threshold Monitoring of Patients Receiving Ototoxic Drugs

  1989cited by this paper
• Vancomycin and the red-man syndrome: pharmacodynamics of histamine release.

  1988cited by this paper
• Survey of Vancomycin Monitoring Guidelines in Illinois Hospitals

  1988cited by this paper
• Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers

  1988cited by this paper
• Nephrotoxicity of vancomycin-gentamicin therapy in pediatric patients.

  1987cited by this paper
• Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

  1987cited by this paper
• Routine monitoring of serum vancomycin concentrations: waiting for proof of its value.

  1987cited by this paper
• In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats.

  1986cited by this paper
• Clinical Pharmacokinetics of Vancomycin

  1986cited by this paper
• Monitoring Vancomycin Therapy

  1986cited by this paper
• Vancomycin enhancement of experimental tobramycin nephrotoxicity

  1986cited by this paper
• Vancomycin and the kidney.

  1986cited by this paper
• A Simplified Dosing Method for Initiating Vancomycin Therapy

  1985cited by this paper
• Vancomycin toxicity: a prospective study.

  1985cited by this paper
• A prospective study of adverse reactions associated with vancomycin therapy.

  1985cited by this paper
• Vancomycin use--an historical review.

  1984cited by this paper
• Vancomycin pharmacokinetics in critically ill patients.

  1984cited by this paper
• Ototoxicity of Oral Neomycin and Vancomycin

  1983cited by this paper
• Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

  1983cited by this paper
• Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia.

  1983cited by this paper
• Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center.

  1982cited by this paper
• Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

  1982cited by this paper
• Vancomycin: a reappraisal.

  1982cited by this paper
• Effects of vancomycin on renal function in rats

  1981cited by this paper
• Vancomycin and interstitial nephritis.

  1981cited by this paper
• Vancomycin Ototoxicity in patient with normal renal function.

  1981cited by this paper
• Clinical pharmacology and efficacy of vancomycin in pediatric patients.

  1980cited by this paper
• Vancomycin therapy of bacterial endocarditis.

  1978cited by this paper
• Vancomycin. A second look.

  1977cited by this paper
• NEPHROTOXICITY OF ANTIMICROBIAL AGENTS — SECOND OF THREE PARTS

  1977cited by this paper
• The treatment of severe staphylococcal infections with vancomycin.

  1961cited by this paper
• Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases.

  1960cited by this paper
• Vancomycin: Report on Treatment of Patients with Severe Staphylococcal Infections

  1959cited by this paper
• Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report.

  1958cited by this paper

• Optimizing Initial Vancomycin Dosing in Hospitalized Patients Using Machine Learning Approach for Enhanced Therapeutic Outcomes: Algorithm Development and Validation Study

  2025cites this paper
• Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury

  2021cites this paper
• Therapeutic Drug Monitoring Coupled with Bayesian Forecasting could Prevent Vancomycin-associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.

  2020cites this paper
• Pharmacoepidemiology and drug safety

  2019cites this paper
• Principles of Antimicrobial Prescription in Intensive Care Unit Patients With Acute Kidney Injury

  2019cites this paper
• Therapeutic drug monitoring: An overview of commonly monitored drugs

  2014cites this paper
• Therapeutic Drug Monitoring in Pediatric Practice: A Critical Appraisal

  2014cites this paper
• Nenatal drug induced nephrotoxicity : old and next generation biomarkers for early detection and management of neonatal drug-induced nephrotoxicity, with special emphasis on uNGAL and on metabolomics.

  2012cites this paper
• Bilateral sensory permanent hearing loss after palliative hypoplastic left heart syndrome operation.

  2012cites this paper
• Clinical pharmacokinetics of vancomycin in the neonate: a review

  2012cites this paper
• An Introduction to Tests Performed in Toxicology Laboratories

  2012cites this paper
• The Use and Misuse of Antibiotics in Neurosurgery

  2011cites this paper
• Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection.

  2011cites this paper
• Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency

  2011cites this paper
• Drug-Induced Nephrotoxicity In The Newborn : The State Of The Art

  2010cites this paper
• Teicoplanin versus vancomycin for proven or suspected infection.

  2010cites this paper
• Vancomycin Pharmacokinetics in Oliguric Patients Undergoing Continuous Venovenous Hemodialysis and Continuous Venovenous Hemodiafiltration

  2010cites this paper
• Ceftriaxone-vancomycin drug toxicity reduction by VRP 1020 in Mus musculus mice.

  2009cites this paper
• Alterações auditivas em recém-nascidos prematuros expostos a antibióticos ototóxicos

  2009cites this paper
• Antioxidant and Blood Brain Barrier Status in Cerebrospinal Fluid of Bacterial Meningitis Rat Model after Vancoplus Treatment

  2009cites this paper
• Cost‐effectiveness analysis of linezolid vs. vancomycin in treating methicillin‐resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model

  2009cites this paper
• Nephrotoxicity Reduction by Ceftriaxone plus Vancomycin (Vancoplus) Reconstituted with VRP 1020 in Blood of Mus musculus Mice

  2009cites this paper
• CHAPTER 65 – Causes and Manifestation of Nephrotoxicity

  2008cites this paper
• Therapeutic Drug Monitoring (TDM) of Antimicrobial Agents

  2008cites this paper
• Introduction to Therapeutic Drug Monitoring

  2008cites this paper
• Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure.

  2006cites this paper
• Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure

  2006cites this paper
• Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients.

  2005cites this paper
• Dados Internacionais de Catalogação na Publicação (CIP)

  2005cites this paper
• Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

  2004cites this paper
• Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model

  2004cites this paper
• Vancomycin: pharmacokinetics and administration regimens in neonates.

  2004cites this paper
• Capítulo 32 – Monitorización de fármacos

  2004cites this paper
• Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia

  2003cites this paper
• Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.

  2003cites this paper
• Mississippi Mud No More: Cost‐Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity

  2003cites this paper
• Dose regimen for vancomycin not needing serum peak levels?

  2002cites this paper
• [Interest in therapeutic drug monitoring of the main antibiotics].

  2002cites this paper
• Structure--activity relationships of 1beta-methyl-2-(5-phenylpyrrolidin-3-ylthio)carbapenems.

  2002cites this paper
• TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients.

  2002cites this paper
• Therapeutic Drug Monitoring in the Newborn

  2002cites this paper
• The therapeutic monitoring of antimicrobial agents.

  2001cites this paper
• Renal Transport of Antibiotics and Nephrotoxicity: a Review

  2001cites this paper
• Recommendations for Monitoring Serum Vancomycin Concentrations

  2001cites this paper
• Concepts for critical appraisal of an original research paper

  2001cites this paper
• In Vitro Activities of Novel trans -3,5-Disubstituted Pyrrolidinylthio-1 b -Methylcarbapenems with Potent Activities against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa

  2000cites this paper
• Vancomycin-Induced Lupus Erythematosuslike Reaction

  2000influential citation
• In Vitro Activities of Noveltrans-3,5-Disubstituted Pyrrolidinylthio-1β-Methylcarbapenems with Potent Activities against Methicillin-Resistant Staphylococcus aureus andPseudomonas aeruginosa

  2000cites this paper
• Optimisation of Vancomycin Regimen in Neutropenic Haematological Patients with Normal Renal Function

  2000cites this paper
• Antibiotics in neonatal infections: a review.

  1999cites this paper
• Antibiotics in Neonatal Infections

  1999cites this paper
• The therapeutic monitoring of antimicrobial agents.

  1999cites this paper
• Antibacterial-Induced Nephrotoxicity in the Newborn

  1999cites this paper
• Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

  1998cites this paper
• Failure of Once‐Daily Vancomycin for Staphylococcal Endocarditis

  1998cites this paper
• Chapter 5 – Drug Interactions with Antimicrobial Agents

  1997cites this paper
• Delayed Hypersensitivity Reaction to Vancomycin

  1997cites this paper
• The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin

  1997cites this paper
• A closer look at vancomycin, teicoplanin, and antimicrobial resistance.

  1997cites this paper
• Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

  1996cites this paper
• Cost‐effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

  1996cites this paper
• Why monitor peak vancomycin concentrations?

  1995cites this paper
• Why monitor peak vancomycin concentrations?

  1995cites this paper
• Vancomycin administration and monitoring reappraisal.

  1995cites this paper
• Why monitor peak vancomycin concentrations?

  1995cites this paper
• Why monitor peak vancomycin concentrations?

  1994cites this paper